A retrospective,non interventional,multicenter study to evaluate efficacy and safety of Ombitasvir/paritaprevir/ritonavir with and without Dasabuvir Coadministered with and without Ribavirin in Adults With Genotype 1 or 4 Chronic Hepatitis C Virus Infection and Human Immunodeficiency Virus coinfection with chronic kidney disease

Trial Profile

A retrospective,non interventional,multicenter study to evaluate efficacy and safety of Ombitasvir/paritaprevir/ritonavir with and without Dasabuvir Coadministered with and without Ribavirin in Adults With Genotype 1 or 4 Chronic Hepatitis C Virus Infection and Human Immunodeficiency Virus coinfection with chronic kidney disease

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Dasabuvir; Ritonavir
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Vie-KinD
  • Most Recent Events

    • 04 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top